Advertisement

Current Rheumatology Reports

, Volume 13, Issue 3, pp 225–232 | Cite as

Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon

  • Lily Kao
  • Lorinda Chung
  • David F. Fiorentino
Article

Abstract

Dermatomyositis is a systemic autoimmune disease that primarily affects skeletal muscle, skin, and the lungs. Dermatomyositis is characterized by autoantibodies, tissue inflammation, parenchymal cell damage and death, and vasculopathy. This review focuses on recent advances regarding the role of cytokines and interferon in the pathogenesis of the disease. Evidence for the role of a particular cytokine is based on data showing dysregulated levels in tissue and/or blood; correlation with histopathologic or clinical markers of disease activity; and, rarely, clinical efficacy of targeted cytokine inhibitors. Many of the recent advances pertain to elucidation of the role of interferons in both muscle and skin disease in dermatomyositis. Although a great deal of progress has been made regarding the role of interferon in the disease, many critical questions remain unanswered.

Keywords

Dermatomyositis Interferon Cytokine Interface dermatitis 

Notes

Disclosure

Dr. Fiorentino has served as a consultant for MedImmune. Drs. Kao and Chung reported no potential conflicts of interest relevant to this article.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Caproni M et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004;151(4):784–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Greenberg SA, Fiorentino D. Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol. 2009;160(2):464–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):177–90.PubMedCrossRefGoogle Scholar
  5. 5.
    De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21(6):610–6.PubMedCrossRefGoogle Scholar
  6. 6.
    • Mamyrova G, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 2008;58(12):3941–50. This was a large study of JDM patients showing that multiple TNF-α and IL-1 polymorphisms are risk and protective factors for JDM and that the TNF-α-308A allele has a much higher relative importance compared with all detected risk and other TNF-α and IL-1 cytokine polymorphisms.PubMedCrossRefGoogle Scholar
  7. 7.
    Niewold TB et al. Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. 2010;157(4):653–7.PubMedCrossRefGoogle Scholar
  8. 8.
    • Dastmalchi M, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–7. This study combined clinical, serologic, and histopathologic data from muscle to document that flares in DM (and other inflammatory myopathies) are seen following infliximab therapy, and provides some molecular evidence that these flares are associated with increased IFN activity in the blood and muscle. PubMedCrossRefGoogle Scholar
  9. 9.
    Ishikawa Y et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Marino M et al. IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts. J Neuroimmunol. 2008;196(1–2):41–8.PubMedCrossRefGoogle Scholar
  11. 11.
    • Tournadre A, Lenief V, Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010;62(7):2144–51. This was the first demonstration of TLR3 and TLR7 expression by inflammatory cells and myoblasts in DM, demonstrating preferential expression in regenerating myoblasts that is stimulated by dying myoblasts or nucleic acids, which might provide a mechanism for feed-forward acceleration of IFN production and inflammation. PubMedGoogle Scholar
  12. 12.
    •• Bilgic H, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436–46. Investigators showed a positive correlation between blood levels of three IFN-induced chemokines, IL-6, and disease activity in DM. It is the largest study to date to correlate validated clinical activity measures with levels of circulating candidate biomarker proteins in adult patients with DM. PubMedCrossRefGoogle Scholar
  13. 13.
    Sugiura T et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002;14(8):917–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Suzuki J et al. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol. 2001;28(11):2389–91.PubMedGoogle Scholar
  15. 15.
    Mielnik P, et al. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2010.Google Scholar
  16. 16.
    Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum. 2004;50(1):199–208.PubMedCrossRefGoogle Scholar
  17. 17.
    Szodoray P et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010;49(10):1867–77.CrossRefGoogle Scholar
  18. 18.
    Tucci M et al. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann NY Acad Sci. 2007;1107:184–92.PubMedCrossRefGoogle Scholar
  19. 19.
    Gono T et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010;49(10):1878–81.CrossRefGoogle Scholar
  20. 20.
    Krystufkova O et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68(6):836–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Antiga E et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun. 2010;35(4):342–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Hagiwara E et al. Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyositis. Clin Exp Rheumatol. 1996;14(5):485–91.PubMedGoogle Scholar
  23. 23.
    Hassan AB et al. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun. 2006;27(1):62–8.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6(1):40–9. This is an outstanding review of IFN and its relationship to autoimmunity. PubMedCrossRefGoogle Scholar
  25. 25.
    Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther. 2010;12 Suppl 1:S4.PubMedGoogle Scholar
  26. 26.
    Greenberg SA et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–78.PubMedCrossRefGoogle Scholar
  27. 27.
    Magro CM, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37(6):659–71.Google Scholar
  28. 28.
    Eloranta ML et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112–24.PubMedCrossRefGoogle Scholar
  29. 29.
    Kea B, Pesich R, Chung L, Brown P, Fiorentino D. Genomic analyses identify abnormalities in lipid metabolism in dermatomyositis patients. J Invest Dermatol. 2007;127(S1):12.Google Scholar
  30. 30.
    •• Wenzel J, Tuting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis”. J Invest Dermatol. 2008;128(10):2392–402. This is an excellent review of the relationship between IFN signature and interface dermatitis in the skin. PubMedCrossRefGoogle Scholar
  31. 31.
    Walsh RJ et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Baechler EC et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1–2):59–68.PubMedGoogle Scholar
  33. 33.
    •• Salajegheh M, et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol. 2010;67(1):53–63. This was the first report to indicate that the ubiquitin conjugating system is activated in the muscle of DM patients and that abnormal protein conjugates with ISG-15 protein are present in tissue and inducible by type 1 IFN. It correlates expression of these proteins involved in conjugation with perifascicular atrophy of muscle fibers. PubMedCrossRefGoogle Scholar
  34. 34.
    Fall N et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005;52(10):3175–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Wenzel J et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol. 2006;31(4):576–82.PubMedCrossRefGoogle Scholar
  36. 36.
    O’Connor KA et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol. 2006;120(3):319–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Lovgren T et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861–72.PubMedCrossRefGoogle Scholar
  38. 38.
    • Krol P, et al. Serum levels of interferon {alpha} do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis. 2010. This study failed to find a positive correlation with circulating IFN-α levels and muscle disease activity in patients with DM as measured by MRI of muscles. It suggests that the relationship between IFN-α levels, the IFN signature in blood, and disease activity in DM is complex. Google Scholar
  39. 39.
    Stone KB et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Hua J et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54(6):1906–16.PubMedCrossRefGoogle Scholar
  41. 41.
    Niewold TB et al. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60(6):1815–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Sugiura T et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000;164(12):6593–600.PubMedGoogle Scholar
  43. 43.
    Lundberg I et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40(5):865–74.PubMedCrossRefGoogle Scholar
  44. 44.
    MedImmune LLC A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis. In: ClinicalTrials.gov [Internet] 2000- [cited 2010 Dec 16]; Available from: http://clinicaltrials.gov/ct2/show/NCT00533091 NLM Identifier: NCT00533091.
  45. 45.
    Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234(1):142–62.PubMedCrossRefGoogle Scholar
  46. 46.
    • McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008;35(5):452–6. This is a comparison of the histologic location of pDCs in the skin of DM patients versus lupus patients. This paper provides evidence suggesting that pDCs might have different functions in different autoimmune skin diseases due to their different locations. PubMedCrossRefGoogle Scholar
  47. 47.
    de Padilla CM Lopez et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007;56(5):1658–68.CrossRefGoogle Scholar
  48. 48.
    Shrestha S et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010;62(9):2813–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Zahn S, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131(1):133–40.Google Scholar
  50. 50.
    Fleming JN et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE. 2008;3(1):e1452.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Immunology and RheumatologyStanford University School of MedicinePalo AltoUSA
  2. 2.Division of Immunology and RheumatologyStanford University School of MedicinePalo AltoUSA
  3. 3.Department of DermatologyStanford University School of MedicineRedwoodUSA

Personalised recommendations